Kenji Fukuno
Takayama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: July 30, 2026
Characteristics of Clinical Response in Patients With Chronic Myeloid Leukemia With an ABL1 In-Frame Exon 4 Deletion: A Multicenter Retrospective Study.
Journal: EJHaem
Published: June 27, 2026
Acquired Pure Red Cell Aplasia Following BNT162b2 mRNA COVID-19 Vaccination.
Journal: Internal medicine (Tokyo, Japan)
Published: February 15, 2026
Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study.
Journal: Annals of hematology
Published: July 13, 2025
Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High-Dose Cytarabine-Based Chemotherapy as Second-Line Treatments for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Journal: Hematological oncology
Published: May 21, 2025
Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine.
Journal: Hematology reports
Published: December 02, 2023
Autoimmune-acquired coagulation factor V deficiency with hyperfibrinolytic disseminated intravascular coagulation.
Journal: International journal of laboratory hematology
Published: September 27, 2023
Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population.
Journal: Scientific reports
Published: February 10, 2023
Prognostic impact of the controlling nutritional status score in patients with peripheral T-cell lymphoma.
Journal: Leukemia & lymphoma
Published: December 30, 2021
A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma.
Journal: Experimental hematology & oncology
Published: October 26, 2021
R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Journal: Hematological oncology
Published: August 03, 2017
Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics.
Journal: Leukemia & lymphoma
Published: September 25, 2014
Last Updated: 09/26/2026